Bridge to Life develops organ preservation solutions and perfusion technologies, including the VitaSmart Hypothermic Oxygenated Perfusion (HOPE) System and the Belzer UW preservation franchise. The VitaSmart system received FDA De Novo clearance in January 2026 and the company reports rapid adoption by leading academic transplant centers, master service agreements, and repeat orders. Bridge to Life is advancing a science-based organ viability assessment tool that is currently investigational and not cleared for commercial sale. The company plans to expand its portfolio beyond liver transplantation into additional organ applications over the next three years and is developing next-generation closed systems to streamline transport. The recent financing was used both to accelerate commercial rollout in the U.S. and to refinance existing debt, reflecting the company’s shift to a fully commercial organization. Bridge to Life is headquartered in Duluth, Georgia.

Total raised

$168M

Funding rounds

6

Latest round

Series C

Latest activity

Aug 2026